EGFR and neoplasm: Transient oxygenation enhancements in the tumor were obtained after intravenous administration of the VEGFR targeting small molecule TKIs axitinib (Inlyta®) and sunitinib (Sutent®), but not following treatment with the EGFR targeting inhibitor erlotinib (Tarceva®).